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Summary
 
We studied the cellular basis of self tolerance of B cells specific for brain autoantigens using
transgenic mice engineered to produce high titers of autoantibodies against the myelin oligo-
dendrocyte glycoprotein (MOG), a surface component of central nervous system myelin. We
 
generated “knock-in” mice by replacing the germline J
 
H
 
 locus with the rearranged immuno-
globulin (Ig) H chain variable (V) gene of a pathogenic MOG-specific monoclonal antibody.
In the transgenic mice, conventional B cells reach normal numbers in bone marrow and pe-
riphery and express exclusively transgenic H chains, resulting in high titers of MOG-specific
serum Igs. Additionally, about one third of transgenic B cells bind MOG, thus demonstrating
the absence of active tolerization. Furthermore, peritoneal B-1 lymphocytes are strongly de-
pleted. Upon immunization with MOG, the mature transgenic B cell population undergoes
normal differentiation to plasma cells secreting MOG-specific IgG antibodies, during which
both Ig isotype switching and somatic mutation occur. In naive transgenic mice, the presence
of this substantial autoreactive B cell population is benign, and the mice fail to develop either
spontaneous neurological disease or pathological evidence of demyelination. However, the
presence of the transgene both accelerates and exacerbates experimental autoimmune encepha-
litis, irrespective of the identity of the initial autoimmune insult.
Key words: B cell tolerance • gene targeting • autoantibodies • experimental autoimmune 
encephalomyelitis • myelin oligodendrocyte glycoprotein
 
S
 
elf tolerance within the B cell compartment is orga-
nized in a highly complex fashion. On the one hand, it
 
is known that the normal B cell repertoire includes a large
number of self-reactive clones, most of which are CD5
 
1
 
polyreactive B cells of the B-1 compartment (1, 2). In con-
trast, in the conventional B-2 B cell subset, autoreactive
clones capable of initiating pathological Ab responses are
either removed via deletion (3–5), silenced by mechanisms
of anergy (6, 7), or defused by receptor editing (8–10).
How can the immune system discriminate between
harmless self-reactive B cell clones and those with a patho-
genic potential? This question is of paramount importance,
as several human diseases are caused by pathogenic B cell
responses that bypass these tolerogenic mechanisms. Exam-
ples include autoimmune hemolytic anemias (11), Graves’
disease (12), skin-blistering diseases (13), myasthenia gravis
(14), and Rasmussen’s encephalitis (15). Autoantibody re-
sponses are also implicated in the pathogenesis of Guillain-
Barré syndrome, motor neuropathies, and multiple sclerosis
(16).
In this study, we have used MOG
 
1
 
 as a model central
nervous system (CNS) autoantigen to investigate the mech-
anisms that normally confer B cell tolerance to antigens se-
questered within the CNS compartment. MOG is a minor
component of CNS myelin that is expressed on the surface
of myelin exclusively in the CNS (17). We have used a
knock-in mutant mouse model to study the development
and control of conditionally pathogenic B lymphocytes in
vivo. We replaced in embryonic stem (ES) cells the ge-
nomic region containing the J
 
H
 
 segments and the DQ52 el-
 
1
 
Abbreviations used in this paper:
 
 AP, alkaline phosphatase; BBB, blood–
brain barrier; CNS, central nervous system; EAE, experimental autoim-
mune encephalomyelitis; ES, embryonic stem; MOG, myelin oligoden-
drocyte glycoprotein; PLP, proteolipid protein; r, recombinant; R/S ratio,
ratio of replacement to silent mutations.
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ement with the rearranged VDJ gene of the H chain from
the MOG-specific hybridoma 8.18-C5 (18). This strategy,
rather than the construction of conventional transgenic
mice, was chosen to allow study of all aspects of B cell dif-
ferentiation, in particular H chain isotype switch as well as
tolerizing events within the natural context of the Ig H
genes, such as V gene editing (19, 20) and the different
tolerogenic potential of different Ig isotypes (21).
This mouse model offers several advantageous features. In
these gene-targeted mice, almost all B cells express transgenic
Ig H chains exclusively, as identified using both allotypic and
idiotypic markers. The transgenic H chains associate with
endogenous Ig L chains to generate large populations of
MOG-reactive B cells in both the bone marrow and pe-
riphery, accounting for 
 
z
 
30% of total B cells. As a conse-
quence, high titers of MOG-specific Igs are found in the
serum of naive knock-in mice but not in naive nontrans-
genic littermates. Finally, the transgenic B cells are condi-
tionally pathogenic: the mutant mice do not spontaneously
develop any neurological deficits. However, when chal-
lenged with encephalitogenic antigens or T cells, the auto-
immune potential of B cells in the transgenic mice unfolds to
increase incidence, severity, and accelerated disease onset of
experimental autoimmune encephalomyelitis (EAE).
 
Materials and Methods
 
Construction of the Targeting Vector.
 
A 1.7-kb genomic region
containing a rearranged V
 
H
 
DJ
 
H
 
 gene (designated Th gene) was
subcloned from hybridoma clone 8.18-C5 (18) and ligated to a
PGK-neo gene in opposite transcriptional orientation. The Th
gene spanning from an EcoRI site 1.1 kb upstream of the ATG
codon to a BamHI site 160 bp downstream of J
 
H
 
2 had been tested
previously for functional expression by transfection into the my-
eloma line X63-Ag8.6.5.3 (not shown). 5
 
9
 
 and 3
 
9
 
 homologous se-
quences were derived from a cosmid clone isolated from an ES
cell genomic library (a generous gift of S. Mudgett and R. Jae-
nisch, Whitehead Institute for Bio medical Research, Depart-
ment of Biology, Cambridge, MA). The cosmid was reduced in
size so that the J
 
H
 
 cluster was flanked by a 12-kb region upstream
and a 1-kb sequence downstream of J
 
H4
 
 including the H chain
enhancer. The DQ52/J
 
H1–4
 
 region was then deleted and replaced
by the neo-Th gene cassette. The final targeting construct (see
Fig. 1) was linearized at a unique NotI site and used for transfection.
 
Homologous Recombination in ES Cells.
 
ES cells of the R1 line
(22) were transfected with the NotI-linearized targeting vector
and selected with G418 as described (23). Southern blot analysis
was performed with SacI-digested ES cell DNA and hybridized to
a 0.8-kb 
 
32
 
P-labeled external probe (see Fig. 1, probe 0.8E
 
H
 
). We
obtained 4 correctly targeted clones out of 320 G418-resistant ES
cell clones and confirmed the mutation by sequencing of PCR-
amplified DNA. Two of these positive clones were injected into
C57Bl/6 blastocysts and reimplanted into pseudopregnant hosts.
Both clones yielded germline-transmitting chimeras. These chi-
meric mice were crossed with C57Bl/6, and agouti offspring were
screened for the Th mutation by Southern blot as above.
 
Flow Cytometry of Lymphocytes.
 
Single cell suspensions were
prepared from spleen, LNs, peritoneal cells, and bone marrow
from 6–8-wk-old mice and processed. Red blood cells were lysed
by incubation in 0.165 M NH
 
4
 
Cl for 10 min. Cells were washed
with PBS/1% FCS and stained with the following Ab conjugates:
anti–IgM
 
a
 
-FITC (clone DS-1; PharMingen, San Diego, CA);
anti–IgM
 
b
 
-BIOTIN (clone AF6-78; PharMingen); anti–CD43-
FITC (clone S7; PharMingen); anti–B220-PE (PharMingen);
anti–CD5-FITC (clone 53-7.3; PharMingen); anti-IgD (Nordic
Immunology Labs, Tilburg, The Netherlands); and 8.18-C5 idio-
type–specific Ab (24). Biotinamidocaproate-
 
N
 
-hydroxysuccin-
imide ester (Sigma Chemical Co., Munich, Germany) was used for
biotin labeling of recombinant truncated rat MOG (25), which was
applied in a 1:500 dilution for staining. Biotin conjugates were de-
veloped with streptavidin-PE (Becton Dickinson, San Jose, CA), and
the 8.18-C5 idiotype–specific Ab was detected with Cy3-labeled
anti–rabbit Ig Ab (Jackson ImmunoResearch Labs, West Grove,
PA). After excluding dead cells by staining with propidium io-
dide, cells were analyzed with a FACScan
 
Ò
 
 (Becton Dickinson).
 
Serum ELISA and Western Blot Analysis.
 
Peripheral blood of
mice was taken by tail bleeding, and after coagulation at 4
 
8
 
C, se-
rum was obtained by centrifugation. For ELISA, 96-well vinyl as-
say plates (Costar Corp., Cambridge, MA) were coated with one
of the following reagents at a concentration of 10 
 
m
 
g/ml in PBS/
0.02% NaN
 
3
 
: goat anti–mouse IgM (Southern Biotechnology As-
sociates, Inc., Birmingham, AL); recombinant MOG (rMOG);
and synthetic peptides spanning the extracellular domain of
MOG. The expression and purification of rat rMOG were de-
scribed previously as well as the composition of the synthetic
MOG-peptides (25, 26). After blocking with 1% BSA, the assay
plates were incubated with serial dilutions of mouse serum. Spe-
cific binding was detected with alkaline phosphatase (AP)-conju-
gated goat anti–mouse IgG (Southern Biotechnology Associates,
Inc.), biotinylated anti-IgM
 
a
 
 and anti-IgM
 
b
 
 (PharMingen), and
streptavidin-coupled AP (Amersham International, Buckingham-
shire, UK) as a secondary reagent. 
 
p
 
-Nitrophenyl phosphate
(Sigma Chemical Co.) was used as a substrate for the AP-cata-
lyzed reaction. The absorbance at 405 nm was read on an ELISA
reader (MR-4000; Dynex Technologies, Denkendorf, Germany).
For Western blot analysis, 20 
 
m
 
g of mouse brain–extracted pro-
teins and rMOG were run on a 12.5% polyacrylamide gel and
transferred to a nitrocellulose membrane (Hybond-ECL; Amer-
sham International). The blot was probed with 1:500 diluted
mouse serum or with the 8.18-C5 mAb in a concentration of 4
 
m
 
g/ml. Specific binding was detected with peroxidase-conju-
gated goat anti–mouse Ig (1:4,000; Amersham International) ap-
plying the ECL system (Amersham International).
 
Cloning and Sequence Analysis of H Chain Sequences.
 
Spleens were
taken from naive and rMOG-immunized mice and immediately
frozen in liquid nitrogen. Total RNA was extracted with Trissolv
reagent (GIBCO BRL, Eggenstein, Germany) according to the
manufacturer’s instructions. cDNAs were synthesized from 10 
 
m
 
g
freshly dissolved total RNA per cDNA reaction using Superscript
reverse transcriptase (GIBCO BRL) with oligo(dT) as a primer.
The resulting cDNA was diluted to 100 
 
m
 
l, and 2 
 
m
 
l of each sam-
ple (corresponding to 200 ng of total RNA) was used for PCR
amplification with the following primers: 5
 
9
 
 primer, 8.18FR1:
CGGGATCCACTCCCAGGTTCAGCTGC, and a 3
 
9
 
 located
C
 
g
 
 primer (27). PCR reactions were carried out using the fol-
lowing conditions: 94
 
8
 
C for 5 min (1 cycle); 94
 
8
 
C for 60 s, 60
 
8
 
C
for 60 s, 72
 
8
 
C for 120 s (30 cycles), followed by a final step of 10
min at 72
 
8
 
C. The PCR products were purified from an ethidium
bromide–stained agarose gel and cloned into pBluescript (Strat-
agene Inc., Heidelberg, Germany) using the restriction endonu-
clease BamHI. Several transformed bacterial clones were analyzed
by DNA sequencing; the sequencing reaction was performed by
MediGene (Martinsried, Germany). 
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Immunization of Mice and Evaluation of EAE.
 
C57Bl/6 mice were
obtained from the animal facility at the Max-Planck-Institut für
Biochemie, and SJL mice were purchased from Charles River
WIGA GmbH (Sulzfeld, Germany). Transgenic F1 (129/Sv 
 
3
 
Bl/6) progeny of chimeric mice were bred onto the C57Bl/6 and
the SJL strain to perform EAE experiments. Mice of the fourth
backcross to SJL were injected with an emulsion of 200 
 
m
 
g pro-
teolipid protein (PLP) 139–154 (28) in CFA (GIBCO BRL) sup-
plemented with 4 mg/ml inactivated 
 
Mycobacterium tuberculosis
 
(H37 RA; Difco Laboratories, Inc., Detroit, MI) in the flanks on
both sides and the tail base. The animals received an additional
intraperitoneal injection of 200 ng pertussis toxin (List Biological
Labs, Inc., Campbell, CA) in 0.1 ml PBS on the day of immuni-
zation and again 48 h later. Mice bred onto the C57Bl/6 genetic
background were immunized with 50 
 
m
 
g rMOG in the same
way as described above, but without the use of pertussis toxin.
Animals were monitored daily for clinical symptoms and weight.
For the clinical evaluation of EAE, the following scale was
used: 0, no clinical disease; 1, tail weakness; 2, paraparesis (in-
complete paralysis of one or two hindlimbs); 3, paraplegia (com-
plete paralysis of one or two hindlimbs); 4, paraplegia with fore-
limb weakness or paralysis; and 5, moribund or dead animals.
To analyze the neuropathology, mice were perfused with 4%
paraformaldehyde. Brain and spinal cord were removed, postfixed
for another 24 h, and routinely embedded in paraffin. The extent
of inflammation and demyelination was evaluated on 3-
 
m
 
m spinal
cord cross sections stained with hematoxylin/eosin and Klüver
Barrera myelin stain.
 
T Cell Lines.
 
SJL mice were immunized with 100 
 
m
 
g of pep-
tides PLP 139–154 and PLP 130–151 (28) for establishment of T cell
lines GK and IH, respectively. 10 d later, cells isolated from drain-
ing LNs were cultured at 5 
 
3
 
 10
 
6
 
 cells/ml in the presence of 10
 
m
 
g/ml PLP peptide for 3 d. After growing cells for 10–14 d in IL-
2–containing DMEM (GIBCO BRL), the cells were restimulated
with antigen and irradiated (4,000 rads) syngeneic spleen cells; the
specificity was assessed by [
 
3
 
H]thymidine (Amersham International)
incorporation for the last 16–18 h of a 3-d culture period. Activated
T cells were harvested on Lymphoprep
 
Ô
 
 (Nycomed, Oslo, Nor-
way), washed once, and injected via the tail vein into mice. Animals
were scored daily for clinical signs of EAE as described above.
Figure 1. Site-directed replacement of the JH
locus with the Thmog gene. (A) Structure and
partial restriction map of the wild-type IgH
locus and the targeted insertion. Filled boxes, the
DQ52 and JH elements; open oval, the 39 en-
hancer region. Arrows, The transcriptional orien-
tation of the Th (VDJ 8.18; hatched box) and the
neor gene. Diagnostic restriction fragments and
location of the probe (0.8 EH) used for Southern
blot analysis are shown. N, NaeI; RI, EcoRI; S,
SacI; Xh, XhoI. (B) Southern blot analysis of ES
cell–derived offspring. SacI-digested tail DNA
from offspring of heterozygous mutant mice was
hybridized to the probe 0.8 EH. Homozygous
mutant animals (Th/Th) show only a 2-kb hy-
bridizing fragment, whereas heterozygous mu-
tants (Th/1) show both a 4- and a 2-kb frag-
ment.
Figure 2. Serum Igs of Th-transgenic mice react specifically with re-
combinant and native brain-derived mouse MOG. (A) Relative concen-
trations of total (top) and MOG-specific (bottom) IgMa and IgMb allotypes
in the blood of 6-wk-old homozygous (Th/Th; n 5 4), heterozygous
mutant (Th/1; n 5 4), and wild-type (1/1; n 5 4) mice by ELISA.
The serum dilutions were 1:50 for measurement of MOG-specific IgMa
and IgMb and 1:6,250 for MOG-specific IgG. Nonspecific binding to
BSA (blocking reagent) was substracted from all values to calculate the
mean absorbance (OD 405 nm) 6 SE. (B) MOG binding specificity of se-
rum Igs derived from homozygous mutant (Th/Th) and wild-type (1/1) mice, analyzed by Western blot. Mouse brain–extracted proteins and rMOG
separated by SDS-PAGE and blotted onto nitrocellulose membrane were incubated with wild-type serum (left), the 8.18-C5 mAb (middle), and serum
from homozygous mutant mice (Th/Th; right). The sizes of the molecular weight standard are indicated (left), and the position of rMOG- and brain-
derived MOG are marked (arrows, right). 
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Results
 
Generation of MOG-specific Ig Gene–targeted Mice.
 
The en-
tire J
 
H
 
 cluster of the Ig H chain gene locus was replaced by
the rearranged VDJ gene segment of MOG-specific mAb
8.18-C5 (Fig. 1 
 
A
 
). Germline chimeric mice generated by
introducing gene-targeted ES cells into blastocysts gave rise
to mutant progeny at normal efficiency (Fig. 1 
 
B
 
). The
transgenic mice were backcrossed onto both C57Bl/6 and
SJL/J genetic backgrounds. Endogenous and transgenic Ig
H chains can be readily identified serologically by their al-
lotypes. C57Bl/6 and SJL/J mice produce Ig of allotype b
(
 
Igh
 
b), whereas the targeted Ig H gene locus is derived from
the strain 129/Sv, with allotype a (Igha).
The total level of serum IgM of the transgenic (a) allotype
in hetero- or homozygous knock-in mice (Th/1 and Th/
Th, respectively) is comparable to the serum levels in F1
mice heterozygous for the IgMa and IgMb alleles (Fig. 2 A).
In contrast to Th/1 heterozygous knock-in mice, where
serum IgMb levels are slightly reduced, no IgMb can be de-
tected in Th/Th mice (Fig. 2 A). MOG-binding IgG and
IgMa are found exclusively in naive Th/Th and Th/1 mice
but not in wild-type nontransgenic F1 mice (Fig. 2 A).
The antigen specificity of the serum Igs derived from
transgenic mice was verified by Western blotting. Sera from
knock-in but not from nontransgenic littermates bound to
rat rMOG, as well as to native mouse brain MOG (Fig. 2
B). The transgenic Abs showed a binding pattern identical
to the MOG-specific “donor” mAb 8.18-C5.
Distribution and Development of B Cells in Th Mice.
Flow cytometric analysis of B lymphocytes obtained from
knock-in animals confirmed that autoreactive MOG speci-
ficity is not confined to a small subpopulation. Abs specific
for transgenic IgM (IgMa) bound to the vast majority of
resting B lymphocytes in the spleen of Th/1 mice, docu-
menting the predominant use of the transgenic Ig H chain.
Only a minority of B cells (1–4%) express endogenous Ig H
chains (Fig. 3 A, top). Staining of these few B cells is not
due to an artifact, but seems to represent a minor IgMb-
labeled subpopulation specific for Th/1 mice, since such
cells are completely absent in Th/Th mice (Fig. 3 C).
Thus, allelic exclusion leads to exclusive expression of the
mutant Ig H allele.
Interestingly, in Th/1, up to 30% and in Th/Th, up to
50% of IgMa-positive B cells bound biotin-tagged, rMOG
protein (Fig. 3, A and C). Using rabbit antiidiotypic Abs
recognizing specifically the V region of the H chain of
8.18-C5 (24), we confirmed that the overwhelming major-
ity of transgenic B cells indeed express the 8.18-C5 VH id-
iotype (Fig. 3 A). This excludes the possibility that editing
of the original gene-targeted V region has occurred within
the IgMa-positive B cell population that is unable to bind
MOG, and suggests that many but not all endogenous L
chains can associate with the transgenic H chain to generate
a functional MOG-specific Ab.
The total number of B and T cells and the distribution of
T cell subsets in the spleen and LNs of both Th/1 het-
erozygous and Th/Th homozygous animals were indistin-
guishable from wild-type control organs (not shown), indi-
cating normal differentiation of transgenic B lymphocytes.
Analysis of early B cell differentiation in the bone marrow
of adult Th/1 mice confirmed this assumption. The num-
ber and distribution of B cell precursors in the bone mar-
row of these mice were identical to that seen in wild-type
littermates as assessed by the surface expression of the dif-
ferentiation markers B220, CD43, and IgM (Fig. 3 B). In
addition, MOG-specific B cells appear in the bone marrow
at a frequency similar to that found in the periphery (Fig. 3,
A and B).
The analysis of the peritoneal B cell compartment, the
main milieu of B-1 lymphocytes, revealed that due to al-
lelic exclusion, the transgenic IgMa H chain was also domi-
nant in the peritoneal B cell population (Fig. 4). The pro-
Figure 3. Surface phenotype of lymphocytes isolated from spleen (A),
bone marrow (B), and peripheral blood (C) of wild-type (1a/1b), het-
erozygous (Tha/1b), and homozygous (Tha/Tha) mutant 8-wk-old mice.
Cells were stained with anti-IgMa mAb, anti-IgMb Mab, biotinylated
rMOG, anti-B220, anti-CD43, and an idiotype-specific Ab (VH
8.18-C5) as
indicated. Numbers in quadrants refer to the percentage of cells in the
lymphocyte gate as defined by forward and side scatter.173 Litzenburger et al.
portion of MOG-binding IgMa B cells was comparable to
that seen in other lymphoid organs (Fig. 4). However, the
proportion of CD51 B-1 subset B cells, characterized by
low levels of IgD and B220, was severely reduced in the
peritoneum of the mutant mice (Fig. 4).
These results demonstrate that association of the targeted
Ig H chain with endogenous L chains generate autoreactive
MOG-specific B cells which differentiate without restric-
tion in the bone marrow and subsequently colonize the
immune organs of Th mice.
Response of Transgenic B Cells to Immunization against
MOG. We have shown that in naive transgenic mice,
neither are autoreactive MOG-specific B cells deleted, nor
are their Ig receptors edited through secondary rearrange-
ments of the transgenic Ig H chain. Also, the density of sur-
face IgM receptors on the populations of B cells that do
and do not bind MOG is identical in transgenic animals
and similar to that seen in nontransgenic littermates. This
argues against anergy of autoreactive B cells (Fig. 3). More
cogent evidence for the functional state of autoreactive
transgenic B cells comes from immunization of Th/1 mice
with recombinant MOG in CFA. This treatment induces a
MOG-specific Ab response, with the synthesis of both
IgG1 and IgG2a Igs, which are indicative of normal isotype
switching (Fig. 5 A).
Our knock-in Th mice are “single-transgenics,” with
only the Ig H chain modified by insertion of a MOG-spe-
cific VDJ region. Therefore, L chains used by transgenic B
lymphocytes are from endogenous origin, and upon immu-
nization with MOG, this diverse L chain use could result in
novel epitope specificities differing from that of the original
8.18-C5 hybridoma. The mAb 8.18-C5 recognizes a non-
linear, conformational but SDS-resistant epitope within the
extracellular Ig-like domain of MOG (our unpublished ob-
servations). This original specificity pattern was maintained
in MOG-immunized Th/1 mice, where no response was
detected to a panel of peptides covering the entire rMOG
protein (Fig. 5 B). In contrast, the Ab response in immu-
nized wild-type littermates recognizes multiple linear
MOG peptide epitopes, mainly located in the amino acid
sequences 1–25 and 50–71 (Fig. 5 B). The absence of these
MOG peptide–specific responses in Th mice strongly sug-
gests that the immune response against MOG in knock-in
mice is dominated by transgenic B cells of the same speci-
ficity as in the original hybridoma 8.18-C5.
Somatic hypermutation of Ig V regions is a hallmark of
the B cell immune response. To document somatic muta-
tions within the targeted VDJ gene, we amplified the gene-
targeted VDJ region linked to constant regions of g iso-
types via reverse transcription PCR from mRNA from the
Figure 4. Flow cytometry of
peritoneal B cells from wild-type
(1a/1b) and heterozygous mu-
tant (Tha/1b) 8-wk-old mice.
Cells were stained with anti-
IgMa and -IgMb allotype–specific
Abs and MOG as shown previ-
ously in Fig. 3. Double stainings
of either CD5 or IgD combined
with anti-B220 identify CD5-
positive B-1 cells, characterized
by low expression of B220 and
IgD. Boxes, B220dullCD51 cells
and B220dullIgDdull cells; percent-
ages in a given box are shown for
each plot.
Figure 5. Ab response of Th-
transgenic mice immunized with
rMOG in CFA. (A) MOG-spe-
cific IgG1 and IgG2a Abs were
measured in the serum (diluted 1:
360) of homozygous mutant
mice (Th/Th; top) and wild-
type controls (1/1; bottom) by
ELISA (see Fig. 2). Samples were
taken before immunization and
7, 14, and 21 d after antigenic
challenge. Two mice of each
group are shown. (B) The
epitope specificity of serum Igs
was analyzed in heterozygous
mutant (Th/1) and wild-type
(1/1) mice 14 d after MOG
immunization. A panel of overlapping peptides spanning the extracellular region of MOG including NH2-terminal (N-term) and COOH-terminal (HIS-
tag) peptides of rMOG was used to measure specific reactivity by ELISA (OD 405 nm). Purified 8.18-C5 mAb (pur. 8.18c5) was used at a concentration
of 2 mg/ml, and the serum was diluted 1:100 and developed with goat anti–mouse Ig.174 Gene Targeting of Anti-MOG Autoantibody
spleens of MOG-immunized homozygous Th/Th mice,
and determined individual sequences after cloning. Re-
placement mutations are already detectable in the transgenic
V region before immunization (Fig. 6). These mutations are
scattered throughout the entire V sequence without marked
accumulation in the CDR3 region (0.06 mutations/amino
acid in the framework regions versus 0.1 in the CDR re-
gions). However, at day 14 after immunization, the total re-
placement to substitution (R/S) ratio (R/S: 3.4) was three
times higher than in preimmune sequences (R/S: 1.4), and
for the CDR3 region, this increase was tenfold (R/S: 1.5 at
day 0 versus R/S: 14.5 at day 14 after immunization; Fig.
6). Although care must be taken correlating sequence data
with antigen specificity, the enhanced frequency of re-
placement mutations in the CDR3 region of the gene-tar-
geted VH gene is indicative of an antigen-driven process.
We conclude that the MOG-specific transgenic B cells
in Th mice arise and develop normally, are not anergized
in peripheral immune organs, and are functionally compe-
tent and fully able to sustain mature humoral immune re-
sponses on immunization with the cognate antigen.
MOG-specific B Cells Are Conditionally Pathogenic. We have
demonstrated the persistence of functionally reactive au-
toreactive MOG-specific B cells in the Th mice, and
showed high titers of MOG-specific serum autoantibody.
Yet the mutant mice developed neither neurological defi-
cits nor CNS pathology during a period of over one year.
The intact endothelial blood–brain barrier (BBB) and in-
trinsic protective mechanisms in the CNS (29) seem to be
sufficient to protect the mice against the potentially patho-
genic B cells and their autoantibody products. However,
the pathogenic potential of this MOG-specific population
of B cells was revealed in the context of a CNS-specific in-
flammatory response.
Th mice were backcrossed onto SJL and C57Bl/6
strains, which differ markedly in their susceptibility to
Figure 6. Somatic hypermutation of the trans-
genic Th gene sequence obtained from homozygous
mutant (Th/Th) mice before (day 0) and 14 d after
priming with rMOG. Deduced amino acid se-
quences are compared with that of the 8.18-C5
gene. Dashes, identity; amino acid substitutions are
shown; dots, silent mutations. The sequence data are
available from GenBank under the accession num-
ber AF042086.
Table 1. Active EAE in 8–12-wk-old Thmog Mice (Th/1) Compared with Littermate Controls (1/1)
Strain backcross level Genotype Antigen
Disease incidence
(percent)
Mean maximal disease
score 6 SE
Mean day of onset
(range)
C57B6-n1 Th/1 rMOG 8/14 (57) 2.9 6 0.44 15.5 (13–18)
1/1 rMOG 1/12 (8) 2.0 21.0
C57B6-n2 Th/1 rMOG 5/6 (83) 2.9 6 0.58 14.6 (13–15)
1/1 rMOG 3/7 (43) 2.3 6 0.33 22.0 (17–28)
C57B6-n3 Th/1 rMOG 9/13 (69) 2.4 6 0.28 21.3 (14–32)
1/1 rMOG 6/16 (38) 3.6 6 0.20 21.7 (20–26)
SJL-n4 Th/1 PLP 139–154 13/14 (93) 4.89 6 0.08 8.6 (7–17)
1/1 PLP 139–154 11/12 (92) 2.14 6 0.32 12.2 (8–25)
Mice of three distinct generations (n1–3) bred into the C57B6 strain and animals of the fourth backcross to SJL (SJL-n4) were challenged with
rMOG and PLP 139–154, respectively (reference 21). The disease incidence, the mean maximal disease score, and the average onset of clinical EAE
were calculated for each group of immunized mice.175 Litzenburger et al.
EAE. Wild-type SJL mice are highly responsive to immu-
nization with either PLP peptide 139–154 or rMOG pro-
tein (reference 28, and our unpublished observations). In
SJL mice actively immunized with the PLP peptide, the
presence of the transgene accelerated disease onset and ag-
gravated the neurological deficit to a mean maximal disease
score of 4.9, as opposed to 2.1 in the littermate controls
(Table 1, and Fig. 7). Histopathological analysis revealed
that accelerated disease development was associated with
widespread CNS inflammation and demyelination by day 9
after immunization in the mutant Th mice, at which time
wild-type controls showed no CNS lesions (Fig. 8). As op-
posed to the relatively mild, relapsing course of disease seen
in nontransgenic littermate mice, EAE actively induced in
transgenic mice with PLP peptide was severe; remission
was observed in only one Th animal, and this was followed
by a fatal relapse (Fig. 7, and Table 1).
In contrast to the high susceptibility of SJL mice, C57Bl/6
mice are PLP resistant and only partially susceptible to EAE
induced with rMOG protein (reference 30, and our un-
published observations). In transgenic C57Bl/6 mice, the
incidence of MOG-induced disease was 70 6 13%,
whereas in wild-type littermates, the incidence was only 29
6 19% (Table 1).
In transgenic SJL mice, disease onset was also accelerated
upon adoptive transfer of PLP peptide–specific SJL T cell
lines. These T cell lines induce severe and ultimately lethal
EAE in normal SJL mice, but disease onset consistently oc-
curred 3–4 d earlier in the SJL-backcrossed Th/1 animals
compared with their littermates, irrespective of the dose of
T cells transferred (Table 2). As the T cell lines are PLP-, not
MOG-specific, we can exclude the possibility of antigen-
dependent cooperation with the transgenic MOG-specific B
cell population that could enhance T cell proliferation or
conversely activate resident B cells. Therefore, the acceler-
ated onset of disease seen in the Th/1 mice probably rep-
resents the pathologic effects of MOG-specific Abs that
rapidly amplify the inflammatory/demyelinating response
in the CNS (31).
Treatments that do not interfere with BBB permeability,
such as pertussis toxin alone, immunization with foreign
antigens such as KLH, or the passive transfer of KLH-spe-
cific T cells, failed to provoke CNS disease in transgenic
mice (data not shown).
Discussion
Numerous studies have used transgenic mice to investi-
gate the mechanisms involved in immunological self toler-
ance of B lymphocytes. For example, in conventional
transgenic mice harboring rearranged Ig genes specific for a
natural self protein (the MHC class I molecule H-2Kk), or a
transgenically expressed foreign protein (hen egg lysozyme),
physical deletion was observed when the autoantigen was
expressed as membrane component, whereas expression of
the autoantigen as soluble protein led to the functional in-
activation, or anergy, of autoreactive B cells (32). Studies of
transgenic mice with Abs against MHC determinants or
against DNA led later to the discovery of B cell receptor
editing, the selective inactivation of the autoreactive Ig re-
ceptor by the reactivation of endogenous Ig gene rear-
rangement, which results in expression of nonautoreactive
endogenous L chains (20, 33).
The picture was sharpened and to some degree modified
with the advent of gene-replacement mutants. In studies
using knock-in mice where some of the germline Ig genes
were replaced with rearranged autoantibody genes (20, 33),
B cell receptor editing, which was localized in the pre–B
cell compartment, proved to be of more substantial impor-
tance than anticipated (20, 34). Further, immunization of
knock-in mice allows mature self-reactive B cells to be
studied in terms of Ig switching and affinity maturation via
somatic mutation.
To date, no transgenic models have been described in-
volving Ig gene replacement with autoantibodies known to
mediate defined tissue-specific autoimmune disease. We
have generated a knock-in mutant in which the VDJ re-
gion of the MOG-specific H chain from the hybridoma
8.18-C5 was inserted into the natural location of rear-
ranged V genes in the H gene locus. mAb 8.18-C5 medi-
ates demyelination both in vitro and in vivo (35, 36) and
exacerbates clinical disease in EAE (31, 37). Apart from
dealing with a proven pathogenic autoantibody, our model
combines several features advantageous for studying devel-
Figure 7. Development of clinical EAE in four
wild type (1/1; top) and four heterozygous mutant
(Th/1; bottom) mice after immunization with pep-
tide PLP 139–154 in CFA. The clinical score (y-
axis) and weight (not shown) were monitored daily
over a period of 40 d (x-axis) after injection. The
shown data are representative of a larger group of
immunized animals summarized in Table 1.176 Gene Targeting of Anti-MOG Autoantibody
opment and maintenance of B cell self tolerance. The presence
of defined allotypic and idiotypic markers allows the trans-
genic H chain to be detected in vivo. Furthermore, the com-
bination of the gene-targeted H chain with endogenous L
chains generates MOG specificity in a fraction but not in all
transgenic B lymphocytes (Fig. 3). This allowed us to study
the maturation of autoreactive B cells under conditions where
they have to compete with a large pool of nonautoreactive
B cells for appropriate immunological niches (38), in both
naive and challenged animals. Finally, the restricted local-
ization of MOG to the CNS allowed us to study the mech-
anistic basis of tolerance for a sequestered antigen and the
role of autoreactive B cell clones in disease development.
The analysis of transgenic B cells in mature immune or-
gans did not provide any evidence of active tolerance in-
duction. Mature mutant mice express the transgenic Ig H
chain in almost all B cells and constitutively synthesize high
levels of MOG-specific Ig. The peripheral immune organs
of adult hetero- and homozygous knock-in Th mice con-
tain B cells indistinguishable from wild-type mice in num-
ber and morphology, ruling out substantial B cell deletion.
Likewise, anergy is also excluded by the normal density of
surface IgM on the transgenic B cells (Fig. 3) and by their
full response to immunization against MOG (Figs. 5 and 6),
suggesting that circulating amounts of soluble MOG, if
present at all, must be negligible (39). Furthermore, using a
VH chain–specific idiotypic marker Ab, we found no evi-
dence of Ig H chain editing (Fig. 3).
The number and composition of immature B lympho-
cyte subsets developing in the transgenic bone marrow
Figure 8. Histological staining on paraffin-embedded spinal cord sections of Th transgenic and wild-type mice after induction of EAE with PLP 139–
154 peptide. On day 9 after immunization, early demyelination is found in Th knock-in animals (B) but not in littermate control mice (A). Large cellular
infiltrates are detectable within the areas of demyelination after hematoxylin/eosin staining of sections of Th mice (D) but not in sections of control ani-
mals (C).177 Litzenburger et al.
were also completely regular. In particular, pro–B cells
(CD431, B220low, IgM2), pre–B cells (CD432, B220low,
IgM2), and immature B cells (B220low, IgM1) did not dif-
fer from the corresponding subsets in the bone marrow of
normal littermate mice (Fig. 3). Further, early B lympho-
cytes bound MOG at high rates similar to those of mature
peripheral B cells, indicating that the peripheral level of
MOG specificity is the result of random association of the
knock-in Ig H chain with endogenous L chains during B
cell development.
The only B cell compartment showing drastic differences
between transgenic and wild-type mice was the peritoneal
space, the habitat of CD51 B-1 lymphocytes (1). In our
transgenic mice, the peritoneal B-1 compartment was se-
verely depleted of CD51 B-1 cells (Fig. 4). This is opposite
to one case of conventional transgenic mice which ex-
pressed the gene for a hemolytic autoantibody predomi-
nantly in the B-1 cell subset, in the absence of B cells of the
B-2 compartment (40). Yet it is doubtful that depletion of
B-1 cells in our transgenic mice is related to B cell self reac-
tivity. In fact, the observation of a similar change in an-
other knock-in model expressing transgenic Ig specific for
foreign antigen (27) would rather argue against an autoim-
mune basis of B-1 cell deficiency.
Immunization of our transgenic mice with rMOG protein
resulted in enhanced Ig levels, isotype switching, and the
accumulation of somatic mutations in the CDR3 sequence,
changes similar to those seen during the conventional antigen-
driven selection process (41). The transgenic VH region
found in IgG-expressing B cells of nonimmunized controls
contains exchange mutations scattered throughout the entire
VDJ gene segment. Since we analyzed homozygous Th/Th
mice in these experiments, these mutations most likely re-
flect the need to select clones recognizing specificities other
than MOG (42).
Remarkably, even after immunization, the Ab response
is dominated by the original epitope specificity of the hy-
bridoma 8.18-C5, despite the pathogenicity of this re-
sponse (Fig. 5 B). We conclude from these observations
that MOG-specific autoreactive B cells in Th knock-in
mice mature uncensored through all stages of B cell differ-
entiation, resulting in a large pool of potentially pathogenic
B cells that produces high titers of autoreactive serum Igs.
The normal distribution and responsiveness of the
MOG-specific B cells in Th mice could be explained by
clonal ignorance, with the target autoantigen inaccessible
during B cell development and maturation. Indeed, MOG
is exclusively produced by oligodendrocytes of the CNS
and is therefore sequestered from the peripheral circulation
by the endothelial BBB. Although there is protein ex-
change between the cerebrospinal fluid and lymph (43), in
the case of MOG, if this occurs at all, the levels of antigen
reaching the periphery are clearly insufficient to induce tol-
erance. However, mature B cells may be able to cross the
BBB. It has already been established that the BBB is per-
meable for activated T cells but not for resting T lympho-
cytes (44). The same rule may also hold for B cells, as sug-
gested by the behavior of activated B cell lymphomas,
which have a marked propensity to cross the BBB (45).
These observations are clinically relevant, as the MOG-
specific transgenic B cells produce conditionally pathogenic
autoantibodies. These B cells fail to cause spontaneous au-
toimmune disease in the healthy organism, but exhibit
their pathogenic potential in combination with an enceph-
alitogenic T cell response. Activated myelin-specific T
lymphocytes cross the BBB shortly after intravenous trans-
fer. The subsequent interaction with glial cells within the
CNS triggers an inflammatory cascade and then results in
the opening of the BBB. This leads to edema formation
and the influx of inflammatory cells and serum proteins
into the CNS (44). Permeating anti-MOG Abs bind to their
target epitopes on the myelin surface and initiate wide-
spread complement- and antibody-dependent cell-mediated
cytotoxicity (ADCC)-mediated demyelination. In addition,
Table 2. Passive EAE in Heterozygous Mutant Mice (Th/1) and Littermate Controls (1/1) Induced by Adoptive Transfer of 
Encephalitogenic T Cells
Strain-backcross level Genotype
No. of cells transferred
(3106)
Line 
(restimulation cycles) EAE incidence
Average day of
onset (range)
SJL-n2 Th/1 6 GK (1) 10/10 4.5 (4–5)
1/1 6 GK (1) 10/10 7.2 (6–9)
SJL-n2 Th/1 5 IH (2) 3/3 4.6 (4–5)
1/1 5 IH (2) 2/3 9.0 (6–12)
SJL-n3 Th/1 1 GK (1) 7/7 5.1 (4–7)
1/1 1 GK (1) 5/5 7.8 (6–10)
SJL-n3 Th/1 0.1 GK (1) 3/4 6.3 (6.7)
1/1 0.1 GK (1) 2/3 10
PLP-specific T cell lines were established from SJL mice as described in Materials and Methods. After one or two cycles of restimulation with anti-
gen, equal numbers of activated T cells were transferred intravenously in Th/1 and 1/1 mice of the second and third backcross to SJL.178 Gene Targeting of Anti-MOG Autoantibody
the autoreactive B cells may also function as highly efficient
APCs, enhancing the selective action of MOG-specific T
cells (46). Deciphering the precise roles played by B cells in
MOG-induced autoimmune disease is of particular interest,
as recent evidence stresses the importance of MOG as a
prominent candidate autoantigen in multiple sclerosis and
the implication of B cells in this disease.
In general terms, our results show that autoreactive B lym-
phocytes with pathogenic potential can develop and respond
to activation in a healthy organism. Comparable autoreac-
tive B cell clones with specificities for other tissue-specific
autoantigens (e.g., thyroid, pancreatic islet, epithelial) are also
likely to be present in the healthy immune repertoire (47).
From this point of view, B cell tolerance resembles its
counterpart on the T cell level, where potentially autoreac-
tive T cell clones are known to be normal components of
the intact immune repertoire (48, 49). In this case, the in-
duction of autoimmune disease requires that autoreactive T
cells must be activated, for example, through microbial
agents (50). Similarly, in the case of autoreactive B cells
specific for CNS antigens, their presence in the immune
system is in itself insufficient to cause tissue damage. This
requires additional inflammatory factors, such as a concom-
itant encephalitogenic T cell response or CNS inflamma-
tion. Alternatively, it could be argued that the high levels
of allelic exclusion reached in our Th mice could have led
to the depletion of the natural Ab repertoire, which has
been suggested to play a role in protecting against autoim-
mune diseases (for a review, see reference 51). However,
an enhanced susceptibility to autoimmunity resulting from
repertoire shift rather than from the MOG specificity of the
targeted H chain seems less likely, since all EAE studies
(Table 1, and Fig. 7) were performed in heterozygous Th/1
mice, which contain almost normal serum titers of non-
transgenic Abs (allotype b), including natural Abs, com-
pared with normal littermate animals (see Fig. 2 A).
In summary, this paper demonstrates that autoreactive B
cells specific for antigens sequestered within the CNS are
not actively tolerized, but persist in the immune repertoire
due to clonal ignorance. The presence of this potentially
pathogenic B cell population is irrelevant in healthy indi-
viduals, but modifies the pathophysiology and clinical
course of inflammatory CNS disease. Therefore, strategies
for immune therapies should take these observations into
account and be designed to ablate the B cell as well as T
cell arm of the autoimmune response in diseases such as
multiple sclerosis.
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